Cancer feature: cnaCOREAD53

A4GALT ARFGAP3 ARHGAP8 ATP5L2 ATXN10 BIK C22orf26 CDPF1 CELSR1 CENPM CERK CTA-299D3.8 CYB5R3 CYP2D6 EFCAB6 FAM109B FAM118A FAM19A5 FBLN1 FLJ27365 GRAMD4 GTSE1 KIAA0930 KIAA1644 LDOC1L LL22NC03-75H12.2 MCAT MPPED1 NAGA NDUFA6 NFAM1 NUP50 PACSIN2 PARVB PARVG PHF21B PKDREJ PNPLA3 PNPLA5 POLDIP3 PPARA PRR5 PRR5-ARHGAP8 RIBC2 RP1-32I10.10 RRP7A SAMM50 SCUBE1 SEPT3 SERHL2 SMC1B SMDT1 SULT4A1 TBC1D22A TCF20 TRMU TSPO TTC38 TTLL1 TTLL12 UPK3A WBP2NL WNT7B

Known Driver Genes: None

Copy number alternation: loss

UNC0379

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer